New clinical trial results show that tolebrutinib reduces the risk of disability progression in non-relapsing secondary progressive MS and is as effective as teriflunomide in relapsing MS.
This National Volunteer Week, we are celebrating the contributions of the members of MS Australia’s Lived Experience Expert Panel, who share why they’re so passionate about volunteering.Â
The Pharmaceutical Benefits Advisory Committee (PBAC) will consider adding ocrelizumab (Ocrevus®) via subcutaneous delivery to the PBS for relapsing remitting MS.
As Australians head toward the 2025 Federal Election, The Raw Nerve, MS Australia’s official podcast, gathered leading experts to explore a crucial question: why should health be a top election priority?
A new international effort to prevent multiple sclerosis (MS) is officially underway, as researchers, clinicians, people living with MS, and MS organisations from around the world gather in Lisbon, Portugal, for the inaugural Global Prevention and Early Detection Initiative workshop.
We are on the cusp of May, the most important month in the global MS calendar.
Researchers have discovered that genetic changes accumulate more rapidly in MS brain lesions than in non-lesion tissue, with distinct patterns emerging in the lesions.
A pilot study has found an existing online cognitive behavioural therapy (CBT) program from Germany is highly acceptable to people with multiple sclerosis (MS) in Australia and achieved reduced levels of MS-related fatigue.
Phase 3 trials did not show a clear advantage of evobrutinib compared to current treatments for people with relapsing MS.
